Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 10, 2009, Pages 1657-1664

  Henley, David B ^a   May, Patrick C ^a   Dean, Robert A ^a   Siemers, Eric R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

secretase inhibitor; A 1 40; A oligomers; A 1 42; Alzheimer's disease; Amyloid beta; Amyloid hypothesis; Amyloid precursor protein; AN1792; Bapineuzumab; Flurbiprofen; LY450139; Semagacestat; Tramiprosate

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ASP 1702; BAPINEUZAMAB; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; BMS 708163; CTS 21166; CYTOCHROME P450 3A4; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GSI 953; HOMOTAURINE; LEAD; MIDAZOLAM; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NIFEDIPINE; NOTCH1 RECEPTOR; PBT2; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ASTHENIA; BRAIN EDEMA; BRAIN LEVEL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LETHARGY; MENINGOENCEPHALITIS; NAUSEA; NONHUMAN; OCCULT BLOOD; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SMALL INTESTINE OBSTRUCTION; SOMNOLENCE; VOMITING;

ALANINE; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AZEPINES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, TRANSGENIC; PHYSIOLOGICAL PROCESSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650407720     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903044982     Document Type: Review

References (43)

1. Jost BC, Grossberg GT. The natural history of Alzheimer's disease: a brain bank study. J Am Geriatr Soc 1995;43:1248-1255
2. Smith GE, O'Brien PC, Ivnik RJ, et al. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology 2001;57:1467-1473 (Pubitemid 32995730)
3. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498
4. Schneider LS. Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatric Med 2001;17:337-358 (Pubitemid 32429334)
5. Irizarry MC, Hyman BT. Alzheimer disease therapeutics. J Neuropathol Exp Neurol 2001;60:923-928
6. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J 2004;23:483-488 (Pubitemid 38282380)
7. Hardy J. New insights into the genetics of Alzheimer's disease. Ann Med 1996;28:255-258 (Pubitemid 26191063)
8. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997;275:630-631 (Pubitemid 27061322)
9. Lippa CF. Familial Alzheimer's disease: genetic influences on the disease process [review]. Int J Mol Med 1999;4:529-536
10. Lesn S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357
11. Siemers ER, Dean RA, Demattos R, et al. New pathways in drug discovery for Alzheimer's disease. Curr Neurol Neurosci Rep 2006;6:372-378 (Pubitemid 44445680)
12. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-132 (Pubitemid 40923411)
13. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30:317-325 (Pubitemid 350307310)
14. Lilly data on file
15. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-604 (Pubitemid 43739900)
16. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid-beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-1038
17. Bateman RJ. Abstract: a-beta turnover in human subjects. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
18. May PC, Yang Z, Li W, et al. Multi-compartmental pharmaco-dynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004;25:65
19. Lanz TA, Karmilowicz MJ, Wood KM, et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006;319:924-933 (Pubitemid 44776398)
20. Pollack SJ, Lewis H. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005;6:35-47
21. De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-522 (Pubitemid 129523590)
22. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits A-beta production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-12882 (Pubitemid 38445862)
23. Milner LA, Bigas A. Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood 1999;93:2431-2448 (Pubitemid 29181173)
24. Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4:473-478 (Pubitemid 47416642)
25. Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-1763 (Pubitemid 44900749)
26. Bellus Health quarterly report, second quarter 2008. Available from: http://www.bellushealth.com/en/pdf/q208-covers-eng.pdf [Last accessed 23 February 2009]
27. Green RC, Schneider LS, Hendrix SB, et al. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18- month multi-center phase 3 trial. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
28. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
29. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A-beta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223 (Pubitemid 351978111)
30. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539 (Pubitemid 34288854)
31. Selkoe JD. Presented at the International Conference on Alzheimer's Disease's (ICAD) 12th Annual Meeting. Chicago, IL, 2008
32. Fox NC, Black RS, Gilman S, et al. AN1792(QS-21)-201 Study. Effects of A-beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572
33. Gilman S, Koller M, Black RS, et al. AN1792(QS-21)-201 Study Team. Clinical effects of A-beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562
34. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic A-beta42 (AN1792) in patients with AD. Neurology 2005;64:94-101 (Pubitemid 40082943)
35. Schenk DB, Rydel RE, May P, et al. Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. J Med Chem 1995;38:4141-4154
36. Meredith J, Thompson L, Toyn J, et al. BMS-708163, a potent and selective γ-secretase inhibitor, decreases CSF Aβ at safe and tolerable doses in animals and humans [abstract HT-01-05]. International Conference on Alzheimer's Disease 26-31 July 2008, Chicago, IL, USA; 2008
37. Jacobsen S, Comery T, Aschmies S, et al. GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease [abstract P2-302]. Alzheimers Demen 2008;4(Suppl 2):T461
38. Wan H, Bard J, Martone R, et al. GSI-953, a potent and selective gamma-secretase inhibitor, modulates Aβ peptides in mice and humans: translating the PK/PD biomarker relationships in different biological compartments between rodent and human [abstract P2-101]. Alzheimers Demen 2008;4(Suppl 2):T548
39. Frick G, Raje S, Wan S, et al. GSI-953, a potent and selective γ-secretase inhibitor - modulation of β amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans [abstract P4-366]. Alzheimers Demen 2008;4(Suppl 2):T781
40. Imbimbo BP. Alzheimer's disease: γ-secretase inhibitors. Drug Discov Today 2008;5(3):169-175
41. Hsu HH, Jacobs A, Yu J, et al. Phase 1 safety and pharmacokinetic profile of single doses of CTS21166 (ASP1702) in healthy males [poster P4-454-3501]. International Conference on Alzheimer's Disease 26-31 July 2008, Chicago, IL, USA; 2008
42. Hey JA, Koelsch G, Bilcer M, et al. Single dose administration of the β-secretase inhibitor CTS21166 (ASP1702) reduces plasma Aβ40 in human subjects [poster P4-422-3497]. International Conference on Alzheimer's Disease 26-31 July 2008, Chicago, IL, USA; 2008
43. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7(9):779-786